We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Fas (TNF Receptor Superfamily, Member 6) (FAS) Antibodies|
|Epitope||AA 1-169 Alternatives|
|Reactivity||Mouse (Murine) Alternatives|
|Conjugate||This FAS antibody is un-conjugated Alternatives|
|1 reference available|
|Supplier||Log in to see|
Product Details anti-FAS AntibodyTarget Details FAS Application Details Handling References for anti-FAS antibody (ABIN2000159) Images
|Specificity||Mouse FAS / CD95|
|Characteristics||Produced in rabbits immunized with purified, recombinant Mouse CD95 (rM CD95, ABIN2007177 NP_032013.2, Met 1-Arg 169,. Total IgG was purified by Protein A affinity chromatography.|
|Purification||purified by Protein A affinity chromatography|
|Sterility||0.2 μm filtered|
|Immunogen||Recombinant Mouse CD95 protein (ABIN2007177)|
Target Details FASProduct Details anti-FAS Antibody Application Details Handling References for anti-FAS antibody (ABIN2000159) Images back to top
|Alternative Name||FAS (FAS Antibody Abstract)|
|Background||CD95 (APO-1/Fas) is an important inducer of the extrinsic apoptosis signaling pathway and therapy induced apoptosis of many tumor cells has been linked to the activity of CD95. is a prototype death receptor characterized by the presence of an 80 amino acid death domain in its cytoplasmic tail. This domain is essential for the recruitment of a number of signaling components upon activation by either agonistic anti-CD95 antibodies or cognate CD95 ligand that initiate apoptosis. The complex of proteins that forms upon triggering of CD95 is called the death-inducting signaling complex (DISC). The DISC consists of an adaptor protein and initiator caspases and is essential for induction of apoptosis. CD95 is also crucial for the negative selection of B cells within the germinal center (GC). Impairment of CD95-mediated apoptosis results in defective affinity maturation and the persistence of autoreactive B-cell clones. Changes in the expression of CD95 and/or its ligand CD95L are frequently found in human cancer. The downregulation or mutation of CD95 has been proposed as a mechanism by which cancer cells avoid destruction by the immune system through reduced apoptosis sensitivity. Thus, CD95 has therefore been viewed as a tumor suppressor. CD95 has been reported to be involved in the activation of NF-kappaB, MAPK3/ERK1, MAPK8/JNK, and the alternate pathways for CTL-mediated cytotoxicity. Accordingly, this protein is implicated in the pathogenesis of various malignancies and diseases of the immune system. The CD95/CD95L system was implicated in the etiology of inflammatory bowel disease (IBD) based, primarily, on the finding that CD95 is highly expressed in the intestinal epithelial cells and that epithelial apoptosis is increased in IBD.|
|Pathways||p53 Signaling, Apoptosis, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity|
Application DetailsProduct Details anti-FAS Antibody Target Details FAS Handling References for anti-FAS antibody (ABIN2000159) Images back to top
ELISA: 0.5-1 μg/mL
This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Mouse FAS. The detection limit for Mouse FAS is 0.0049 ng/well.
|Restrictions||For Research Use only|
HandlingProduct Details anti-FAS Antibody Target Details FAS Application Details References for anti-FAS antibody (ABIN2000159) Images back to top
|Buffer||0.2 μm filtered solution in PBS|
|Handling Advice||Avoid repeated freeze-thaw cycles.|
|Storage||4 °C,-20 °C,-80 °C|
This antibody can be stored at 2°C-8°C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20°C to -80°C. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
|Expiry Date||12 months|
References for anti-FAS antibody (ABIN2000159)Product Details anti-FAS Antibody Target Details FAS Application Details Handling Images back to top
Peter, Legembre, Barnhart: "Does CD95 have tumor promoting activities?" in: Biochimica et biophysica acta, Vol. 1755, Issue 1, pp. 25-36, 2005